We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases (ESPOIR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01091311
Recruitment Status : Completed
First Posted : March 24, 2010
Last Update Posted : June 8, 2011
Information provided by:
Laboratoires Thea

March 19, 2010
March 24, 2010
June 8, 2011
May 2010
December 2010   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01091311 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases
Phase IV Multicentric Study, 30 Patients Suffering of Meibomian Glands Dysfunction.

Multicentric study, open label, uncontrolled phase IV in 30 patients with meibomian glands dysfunction .

Its objective is to Collect information from patients and ophthalmologists specialized in ocular surface and eyelids to anticipate how Blephasteam ® can be optimized.

This study involves 2 visits, visit of Inclusion, J0, then end of study visit, D21.

Between the two visits patients will be treated with Blephasteam ® for 21 days (up to two uses per day) and complete a questionnaire every two days during the first week and then once a week the next two weeks.

Not Provided
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Eyelid Diseases
Device: Blephasteam
Eye lid warming goggles
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2010
December 2010   (Final data collection date for primary outcome measure)
  • Signed and dated informed consent.
  • Male or female up to 4 years old.
  • Known and treated symptomatic Meibomian Gland Diseases, and/or Dry Eye related to MGDs stable since at least a month.
  • Without any active pathology requiring a change in ocular treatments within the last month before inclusion.
  • Best corrected far visual acuity (VA) > 1/10
Sexes Eligible for Study: All
4 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
N° RCB 2010-A00017-32 ( Other Identifier: AFSSAPS )
Not Provided
Not Provided
Not Provided
Laboratoires Thea
Not Provided
Principal Investigator: Christophe Baudouin, Professor Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Principal Investigator: Frédéric Chiambaretta, Professor Centre Hospitalier Universitaire de Clermont Ferrand
Principal Investigator: Serge Doan, Doctor Hopital Bichat
Laboratoires Thea
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP